11.01.08
Daiichi Fine Chemical Co., Ltd. of Japan is set to launch a new clinical trial that will investigate the effect of Pantesin brand pantethine on lipid management and the reduction of cardiovascular risk factors in the North American population. Renowned cardiologist Dr. John Rumberger and the Contract Research Division of KGK Synergize, London, Ontario, Canada, will conduct the randomized, double-blind, placebo controlled study of 150 subjects in two North American locations. Study subjects at low to moderate risk for cardiovascular disease will be treated over a 16-week period, and results are expected by the third quarter of 2009. Sold in Japan for more than 35 years, Pantesin has been available as a dietary supplement in the U.S. since 1992. The new study will be the most expansive ever conducted using North American subjects.